MarginsXMarginsX
Home › Markets › Health Care › MNKD

MannKind Corporation (MNKD)

MNKD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.96
-4.24% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$349.0M
+22.2% on 2024
Net income · 2025
$5.9M
1.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/0001193125-26-073516-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMNKD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2004
SEC CIK0000899460
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$349.0M
Net income$5.9M
Operating income$38.8M
Net margin1.7%
Operating margin11.1%
Revenue growth+22.2%
Cash$74.9M
Total assets$792.2M
P/E (computed)217.0×
P/S (computed)3.6×

Warning signs

Cash runway
7.5 months
$41.3M cash at September 30, 2026
Share count, 1 year
+4.7%
2025-10-24 to 2026-10-23 · +19.3% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$3.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$41.3M cash; operating cash flow -$16.6M a quarter.Report 2026-09-30
Shares outstanding321,640,118 (2026-10-23); 307,070,281 a year earlier; 269,574,654 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Los Angeles, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $259K, sold $3.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$101.9M-$23.2M-$34.5M$41.3M$319.4M$413.4M10-Q 2026-11-05
Q2 2026
2026-06-30
$109.4M-$19.0M-$18.4M$52.9M$319.1M$393.6M10-Q 2026-08-05
Q1 2026
2026-03-31
$90.2M-$16.6M-$5.4M$52.8M$318.7M$360.8M10-Q 2026-05-06
Q4 2025
2025-12-31
$112.0M-$15.9M-$8.0M$74.9M$354.6M$349.0M10-K 2026-02-26
Q3 2025
2025-09-30
$82.1M$8.0M$23.6M$127.4M$109.7M$313.8M10-Q 2026-11-05
Q2 2025
2025-06-30
$76.5M$668K$8.9M$57.0M$36.2M$301.7M10-Q 2026-08-05
Q1 2025
2025-03-31
$78.4M$13.2M-$6.4M$47.3M$36.1M$297.6M10-Q 2026-05-06
Q4 2024
2024-12-31
$76.8M$7.4M$22.6M$46.3M$36.1M$285.5M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72026-08-21
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-07

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.9%
1 month+35.4%
3 months+10.7%
Year to date-27.2%
1 year-18.5%
From 52-week high-33.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GHRSGH Research PLC$18.75-1.83%$1.3B
MLYSMineralys Therapeutics Inc.$14.53-5.22%$1.3B
NKTRNektar Therapeutics$36.44-2.23%$1.2B
AMPHAmphastar Pharmaceuticals Inc.$29.17-0.68%$1.2B
AAPGAscentage Pharma Group International American Depository Shares$13.29-9.10%$1.2B
INVAInnoviva Inc.$18.49-2.84%$1.3B
SLNSilence Therapeutics Plc American Depository Share$19.80-0.15%$1.2B
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier